112 results
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
10 May 24
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
7:01am
to low 20 percent on net sales; and full reimbursement of future KIO-301 research and development expenses.
Reported quantitative functional MRI
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
25 Mar 24
Results of Operations and Financial Condition
7:03am
reimbursement from TOI. Further, we anticipate G&A expenses to remain relatively flat for the year. We believe this balances our
desire … , and commercial milestones; tiered royalties of up to low 20’s on net sales; and reimbursement of KIO-301 research and development expenses.
Completed
8-K
EX-10.2
1a7k vm73kkp6mtu14
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-10.1
s9gso
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
EX-99.1
tlnuaqk9nj4hu9 5bx
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-10.1
t6e0i
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-4.3
x7lt zha0tg6ev
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm
8-K
EX-1.1
3n1lo
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm
424B1
bkp5y05hfu7c
2 Jun 23
Prospectus with pricing info
5:08pm